Organon & Co
USUSDOrganon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- organon.com
- Връзки с Инвеститорите
- organon.com/investor-relations/
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Централа
- Oss, United States
- Изпълнителен Директор
- Joseph T. Morrissey
- Служители
- 10 000
- Основана
- 1923
- Акции в Обращение
- Свободно Търгуеми Акции
- 242.99 млн
- Пазарна Капитализация
- 3.6 млрд USD
- Инсайдери
- 0.46%
- Институционални Инвеститори
- 84.8%
- Отрасъл (SIC)
- Pharmaceutical Preparations
- ISIN
- US68622V1061
- LEI
- 549300AMCKY57OK2CO56
- Коефициент на Изплащане
- 8.6%
- FCF
- 567 млн USD
- Изплащания / FCF
- 3%
- Дълг
- 8.55 млрд USD13 г. FCF
- Дивидентна История
- 5 г.
- Печалба, FCF и изплатени дивиденти — за 12-те месеца до 30.06.2026 (последният отчет на компанията).
- NAV
Описание
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Дивиденти
Organon & Co (0A9W) изплаща дивиденти на тримесечие. Годишно (12 месеца до и включително най-скорошното обявено плащане): 0.08 USD на акция (плащания: 4). Това е около 0.58% от текущата цена на акцията. Според историята на плащанията следващата екс-дивидентна дата се очаква около 17.11.2026. Години непрекъснати дивиденти: 5.
| Екс-Дата | Изплащане | Сума | % | Вид | Тикер |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-09-10 | 0.0200 USD | 0.1/0.6 % | тримесечно | LSE:0A9W |
| 2026-05-11 | 2026-06-11 | 0.0200 USD | 0.2/0.6 % | тримесечно | LSE:0A9W |
| 2026-02-23 | 2026-03-12 | 0.0200 USD | 0.3/1.0 % | тримесечно | LSE:0A9W |
| 2025-11-20 | 2025-12-11 | 0.0200 USD | 0.3/4.6 % | тримесечно | LSE:0A9W |
| 2025-08-15 | 2025-09-11 | 0.0200 USD | 0.2/6.5 % | тримесечно | LSE:0A9W |
| 2025-05-12 | 2025-06-12 | 0.0200 USD | 0.2/9.7 % | тримесечно | LSE:0A9W |
| 2025-02-21 | 2025-03-13 | 0.2800 USD | 1.8/7.2 % | тримесечно | LSE:0A9W |
| 2024-11-12 | 2024-12-12 | 0.2800 USD | 1.5/6.0 % | тримесечно | LSE:0A9W |
| 2024-08-16 | 2024-09-12 | 0.2800 USD | 1.5/6.0 % | тримесечно | LSE:0A9W |
| 2024-05-10 | 2024-06-13 | 0.2800 USD | 1.5/6.0 % | тримесечно | LSE:0A9W |
| 2024-02-23 | 2024-03-14 | 0.2800 USD | 1.5/6.0 % | тримесечно | LSE:0A9W |
| 2023-11-10 | 2023-12-14 | 0.2800 USD | 2.4/9.8 % | тримесечно | LSE:0A9W |
| 2023-08-17 | — | 0.2800 USD | 1.2/4.9 % | тримесечно | LSE:0A9W |
| 2023-05-12 | — | 0.2800 USD | 1.3/5.3 % | тримесечно | LSE:0A9W |
| 2023-02-24 | — | 0.2800 USD | 1.1/4.2 % | тримесечно | LSE:0A9W |
| 2022-11-10 | — | 0.2800 USD | 1.2/4.7 % | тримесечно | LSE:0A9W |
| 2022-08-12 | — | 0.2800 USD | 0.9/3.5 % | тримесечно | LSE:0A9W |
| 2022-05-13 | — | 0.2800 USD | 0.8/2.4 % | тримесечно | LSE:0A9W |
| 2022-02-25 | — | 0.2800 USD | 0.8/1.6 % | тримесечно | LSE:0A9W |
| 2021-11-19 | — | 0.2800 USD | 0.9/0.9 % | тримесечно | LSE:0A9W |
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| Blackrock Inc. | 12.21% | 32.06 млн | 2026-06-30 |
| Pentwater Capital Manage… | 6.89% | 18.1 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 16 млн | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.76% | 15.13 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.54% | 11.91 млн | 2026-06-30 |
| State Street Corporation | 3.68% | 9.66 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.33 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 6.02 млн | 2026-06-30 |
| Goldman Sachs Group Inc | 1.98% | 5.2 млн | 2026-06-30 |
| UBS Group AG | 1.85% | 4.86 млн | 2026-06-30 |
| Geode Capital Management… | 1.83% | 4.82 млн | 2026-06-30 |
| Alliancebernstein L.P. | 1.81% | 4.75 млн | 2026-06-30 |
| Man Group PLC | 1.59% | 4.18 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.45% | 3.82 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 3.01 млн | 2026-06-30 |
| NexPoint Funds I-NexPoin… | 1.03% | 2.71 млн | 2026-06-30 |
| SPDR SERIES TRUST-State… | 0.94% | 2.47 млн | 2026-08-31 |
| iShares Trust-iShares S&… | 0.89% | 2.35 млн | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.54% | 1.41 млн | 2026-08-31 |
| Fidelity Concord Street… | 0.49% | 1.3 млн | 2026-07-31 |
| ALI KEVIN (Chief Executi… | ≈0.11% | 282 731 | 2025-05-05 |
| WALSH MATTHEW M (Chief F… | ≈0.08% | 212 746 | 2026-03-31 |
| MORRISSEY JOSEPH T JR (C… | ≈0.05% | 123 123 | 2026-03-31 |
| STAHLER RACHEL A (Chief… | ≈0.04% | 116 105 | 2026-03-31 |
| FALCIONE AARON (Officer) | ≈0.04% | 101 431 | 2026-03-31 |
| WEAVER KIRKE (General Co… | ≈0.04% | 92 639 | 2026-03-31 |
| NISITA VITTORIO (Officer… | ≈0.03% | 70 619 | 2026-03-31 |
| KARP DANIEL (Officer) | ≈0.03% | 69 547 | 2026-03-31 |
| HOLZBAUR LYNETTE (Office… | ≈0.02% | 52 850 | 2026-05-06 |
| COX CARRIE SMITH (Office… | — | — | 2025-11-12 |
